134 related articles for article (PubMed ID: 24107524)
21. Nebulized glycopyrrolate (Lonhala Magnair) for COPD.
Med Lett Drugs Ther; 2018 Apr; 60(1543):72. PubMed ID: 29667949
[No Abstract] [Full Text] [Related]
22. Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD).
Sechaud R; Renard D; Zhang-Auberson L; Motte Sde L; Drollmann A; Kaiser G
Int J Clin Pharmacol Ther; 2012 Feb; 50(2):118-28. PubMed ID: 22257577
[TBL] [Abstract][Full Text] [Related]
23. Seebri Neohaler and Utibron Neohaler for COPD.
Med Lett Drugs Ther; 2016 Mar; 58(1491):39-41. PubMed ID: 27027687
[No Abstract] [Full Text] [Related]
24. GFF MDI for the improvement of lung function in COPD - A look at the PINNACLE-1 and PINNACLE-2 data and beyond.
Rabe KF
Expert Rev Clin Pharmacol; 2017 Jul; 10(7):685-698. PubMed ID: 28443352
[TBL] [Abstract][Full Text] [Related]
25. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
Singh D; Schröder-Babo W; Cohuet G; Muraro A; Bonnet-Gonod F; Petruzzelli S; Hoffmann M; Siergiejko Z;
Respir Med; 2016 May; 114():84-90. PubMed ID: 27109816
[TBL] [Abstract][Full Text] [Related]
26. NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease.
Vogelmeier C; Banerji D
Ther Adv Respir Dis; 2011 Jun; 5(3):163-73. PubMed ID: 21511677
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi.
Rogliani P; Calzetta L; Ora J; Lipsi R; Segreti A; Matera MG; Cazzola M
Eur J Pharmacol; 2015 Aug; 761():383-90. PubMed ID: 25952728
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
LaForce C; Feldman G; Spangenthal S; Eckert JH; Henley M; Patalano F; D'Andrea P
Int J Chron Obstruct Pulmon Dis; 2016; 11():1233-43. PubMed ID: 27354782
[TBL] [Abstract][Full Text] [Related]
29. A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD.
Kerwin EM; Spangenthal S; Kollar C; St Rose E; Reisner C
Respir Res; 2018 Mar; 19(1):38. PubMed ID: 29506504
[TBL] [Abstract][Full Text] [Related]
30. [The combination of indacaterol and glycopyrronium has effects on symptoms, lung function, and rate of exacerbations in COPD patients].
Ulrik CS
Ugeskr Laeger; 2014 Sep; 176(38):. PubMed ID: 25294211
[TBL] [Abstract][Full Text] [Related]
31. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
Singh D; Corradi M; Spinola M; Papi A; Usmani OS; Scuri M; Petruzzelli S; Vestbo J
Int J Chron Obstruct Pulmon Dis; 2017; 12():2917-2928. PubMed ID: 29062229
[TBL] [Abstract][Full Text] [Related]
32. Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
Mastrodicasa MA; Droege CA; Mulhall AM; Ernst NE; Panos RJ; Zafar MA
Expert Opin Investig Drugs; 2017 Feb; 26(2):161-174. PubMed ID: 28004591
[TBL] [Abstract][Full Text] [Related]
33. Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.
Ismaila AS; Huisman EL; Punekar YS; Karabis A
Int J Chron Obstruct Pulmon Dis; 2015; 10():2495-517. PubMed ID: 26604738
[TBL] [Abstract][Full Text] [Related]
34. Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study.
Rogliani P; Ora J; Puxeddu E; Calzetta L; Cavalli F; Matera MG; Cazzola M
Pulm Pharmacol Ther; 2018 Apr; 49():20-26. PubMed ID: 29294360
[TBL] [Abstract][Full Text] [Related]
35. Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data.
D'Urzo AD; Kerwin EM; Chapman KR; Decramer M; DiGiovanni R; D'Andrea P; Hu H; Goyal P; Altman P
Int J Chron Obstruct Pulmon Dis; 2015; 10():1599-612. PubMed ID: 26316734
[TBL] [Abstract][Full Text] [Related]
36. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
Vestbo J; Papi A; Corradi M; Blazhko V; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Singh D
Lancet; 2017 May; 389(10082):1919-1929. PubMed ID: 28385353
[TBL] [Abstract][Full Text] [Related]
37. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
[TBL] [Abstract][Full Text] [Related]
38. Long-acting muscarinic antagonists for the prevention of exacerbations of chronic obstructive pulmonary disease.
Jones PW
Ther Adv Respir Dis; 2015 Jun; 9(3):84-96. PubMed ID: 25801643
[TBL] [Abstract][Full Text] [Related]
39. Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING).
Marin JM; Beeh KM; Clemens A; Castellani W; Schaper L; Saralaya D; Gunstone A; Casamor R; Kostikas K; Aalamian-Mattheis M
Int J Chron Obstruct Pulmon Dis; 2016; 11():1425-34. PubMed ID: 27418815
[TBL] [Abstract][Full Text] [Related]
40. Glycopyrronium does not affect QT interval in healthy subjects: a randomized, three- period, cross-over, placebo- and positive-controlled study.
Drollmann A; Sechaud R; Pal P; Hara H; Uziel-Fusi S; Winkle P
Int J Clin Pharmacol Ther; 2014 Sep; 52(9):739-45. PubMed ID: 24986094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
